← Back to Search

Propranolol for Post-Traumatic Stress Disorder (PTTM Trial)

N/A
Waitlist Available
Led By Robin Menzies, MBBS FRCPsych (UK) FRCP (C)
Research Sponsored by Mela, Mansfield, M.D.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up visit 2 (week 4)
Awards & highlights

PTTM Trial Summary

This study will compare the responses of subjects with traumatic memories of varying vintages to either propranolol or placebo in a double-blind setting. It is hypothesized that those subjects who receive propranolol will experience less emotional distress when the memory is subsequently reactivated and less spontaneous re-experiences.

Eligible Conditions
  • Post-Traumatic Stress Disorder

PTTM Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~visit 2 (week 4)
This trial's timeline: 3 weeks for screening, Varies for treatment, and visit 2 (week 4) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
The primary endpoint will be changes between the pretreatment and posttreatment scores in the Clinician Assessment Posttraumatic Scale (CAPS), Impact of Event Scale (IES) and Traumatic Memory Description Measure (TMDM) instruments.
Secondary outcome measures
The secondary endpoint will be changes between the treatment and posttreatment score in the other scales used - MINI, ZAS, ZDS and NIHS.

PTTM Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: PropranololActive Control1 Intervention
The protocol of the study requires that two doses of propranolol (regular propranolol 40 mg followed two hours later by long-acting propranolol 60 mg) be given at the first visit, to be taken within one hour of the reactivation of the traumatic memory. Half of the subjects (33) will be randomized to receive propranolol.
Group II: PlaceboPlacebo Group1 Intervention
The protocol of the study requires that two doses of placebo be given at the first visit, to be taken within one hour of the reactivation of the traumatic memory. Half of the subjects (33) will be randomized to receive placebo.

Find a Location

Who is running the clinical trial?

Mela, Mansfield, M.D.Lead Sponsor
Robin Menzies, MBBS FRCPsych (UK) FRCP (C)Principal Investigator

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Journal of Psychiatric ResearchJournal
Effect of Post-retrieval Propranolol on Psychophysiologic Responding During Subsequent Script-driven Traumatic Imagery in Post-traumatic Stress Disorder
Brunet, Alain, Scott P. Orr, Jacques Tremblay, Kate Robertson, Karim Nader, and Roger K. Pitman. 2008. “Effect of Post-retrieval Propranolol on Psychophysiologic Responding During Subsequent Script-driven Traumatic Imagery in Post-traumatic Stress Disorder”. Journal of Psychiatric Research. Elsevier BV. doi:10.1016/j.jpsychires.2007.05.006.
NatureJournal
Fear Memories Require Protein Synthesis in the Amygdala for Reconsolidation After Retrieval
Nader, Karim, Glenn E. Schafe, and Joseph E. Le Doux. 2000. “Fear Memories Require Protein Synthesis in the Amygdala for Reconsolidation After Retrieval”. Nature. Springer Science and Business Media LLC. doi:10.1038/35021052.
clinicaltrials.govStudy
Propranolol Treatment of Traumatic Memories (PTTM)
2010. "Propranolol Treatment of Traumatic Memories (PTTM)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01069159.
All > Trauma
~4 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top